Todd Adkins, MD
Allergy & Immunology · Jackson, MSNPI 1629056502
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $202,237 of the $226,496 with a category attached, or 89.3%. GSK accounts for 92.8% of it on its own, with 34 other manufacturers making up the rest. Reporting peaked in 2023 at $69,574 and has fallen 78.0% since, to $15,287 in 2025. Among allergy & immunology clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 895 payments — averaging $253.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$210K
- Sanofi$4K
- Regeneron Healthcare Solutions, Inc.$2K
- AstraZeneca$2K
- CSL Behring$2K
- Genentech USA, Inc.$1K
- plus $5K from 29 others
What the payments were for
- Consulting fees$3,5752%
- Speaking & faculty fees$202,23789%
- Travel & lodging$3,3701%
- Food & beverage$17,1288%
- Education$1860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 286 | $210,105 |
| Sanofi | 8 | $3,589 |
| Regeneron Healthcare Solutions, Inc. | 95 | $2,120 |
| AstraZeneca | 91 | $2,108 |
| CSL Behring | 68 | $1,889 |
| Genentech USA, Inc. | 59 | $1,418 |
| Novartis | 65 | $1,262 |
| Pfizer | 31 | $568 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $521 |
| Amgen | 23 | $389 |
| Grifols USA, LLC | 20 | $352 |
| AbbVie | 17 | $332 |
| Octapharma USA, Inc. | 11 | $246 |
| Pharming Healthcare, Inc. | 11 | $202 |
| Boehringer Ingelheim | 13 | $183 |
| Kaleo, Inc. | 12 | $168 |
| LEO Pharma Inc. | 9 | $156 |
| Ionis Pharmaceuticals, Inc. | 4 | $144 |
| Shire North American Group Inc | 8 | $124 |
| Teva Pharmaceuticals USA, Inc. | 9 | $110 |
| Merck | 5 | $97 |
| Optinose US, Inc. | 4 | $69 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $67 |
| Insmed, Inc. | 2 | $39 |
| QOL Medical, LLC | 2 | $39 |
| Biocryst US Sales Co., LLC | 2 | $39 |
| Blueprint Medicines Corporation | 1 | $34 |
| Biocryst Pharmaceuticals, Inc. | 2 | $25 |
| Mylan Specialty L.p. | 1 | $18 |
| Philips North America LLC | 1 | $15 |
| Organon | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $14 |
| Cycle Pharmaceuticals Inc | 1 | $14 |
| Incyte Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$226,496 in reported general payments places this provider in the 95th percentile of 28 allergy & immunology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 297 | $251,439 |
| Dupixent PenDupilumab | 48 | $179,916 |
| XolairOmalizumab | 46 | $105,008 |
| Breo ElliptaFluticasone/Vilanterol | 151 | $73,936 |
| NucalaMepolizumab | 16 | $58,148 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 53 | $42,883 |
| Dupixent SyringeDupilumab | 11 | $41,162 |
| Advair HfaFluticasone Propion/Salmeterol | 59 | $27,847 |
| Spiriva RespimatTiotropium Bromide | 32 | $25,541 |
| Azelastine Hcl | 587 | $19,036 |
| Fluticasone Propionate | 1,243 | $16,544 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 135 | $15,679 |
| Levocetirizine Dihydrochloride | 929 | $14,976 |
| SymbicortBudesonide/Formoterol Fumarate | 45 | $12,571 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 341 | $10,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala | $210,105 | $383,523464 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,108 | $55,45598 claims |
| Boehringer IngelheimSpiriva Respimat | $183 | $25,54132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 28 allergy & immunology providers in Mississippi.
Other allergy & immunology in Jackson
- Daniel VenarskeJackson$156K
- Dexter WalcottJackson$154K
- Chelle WilhelmJackson$61K
- Joshua PhillipsJackson$20K
- Claire RosenblattJackson$11K
- James HaltomJackson$11K
- Gailen MarshallJackson$4K
- Sheryll VincentJackson$3K
- Matthew ElliottJackson$862
- Stephen KempJackson$68
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.